AbbVie Inc., adjusted total assets

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Total assets	134,711)	138,805)	146,529)	150,565)	89,115)
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Less: Deferred tax assets²	5,755)	3,020)	2,274)	2,414)	515)
After Adjustment
Adjusted total assets	128,956)	135,785)	144,255)	148,151)	88,600)

¹ Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

² Deferred tax assets. See details »

Download chart

AbbVie Inc., adjusted total liabilities

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Total liabilities	124,314)	121,518)	131,093)	137,468)	97,287)
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Less: Deferred tax liabilities²	1,952)	2,190)	3,009)	3,646)	1,130)
Less: Restructuring reserve	239)	283)	288)	477)	140)
After Adjustment
Adjusted total liabilities	122,123)	119,045)	127,796)	133,345)	96,017)

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Deferred tax liabilities. See details »

Download chart

AbbVie Inc., adjusted stockholders’ equity (deficit)

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Stockholders’ equity (deficit)	10,360)	17,254)	15,408)	13,076)	(8,172)
Adjustments
Less: Net deferred tax assets (liabilities)¹	3,803)	830)	(735)	(1,232)	(615)
Add: Restructuring reserve	239)	283)	288)	477)	140)
Add: Noncontrolling interest	37)	33)	28)	21)	—)
After Adjustment
Adjusted total equity (deficit)	6,833)	16,740)	16,459)	14,806)	(7,417)

¹ Net deferred tax assets (liabilities). See details »

Download chart

AbbVie Inc., adjusted capitalization table

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Short-term borrowings	—)	1)	14)	34)	—)
Current portion of long-term debt and finance lease obligations	7,191)	4,135)	12,481)	8,468)	3,753)
Long-term debt and finance lease obligations, excluding current portion	52,194)	59,135)	64,189)	77,554)	62,975)
Total reported debt	59,385)	63,271)	76,684)	86,056)	66,728)
Stockholders’ equity (deficit)	10,360)	17,254)	15,408)	13,076)	(8,172)
Total reported capital	69,745)	80,525)	92,092)	99,132)	58,556)
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Add: Current operating lease liabilities (included in Accounts payable and accrued liabilities)²	166)	166)	178)	175)	109)
Add: Noncurrent operating lease liabilities (included in Other long-term liabilities)³	735)	754)	713)	832)	251)
Adjusted total debt	60,286)	64,191)	77,575)	87,063)	67,088)
Adjustments to Equity
Less: Net deferred tax assets (liabilities)⁴	3,803)	830)	(735)	(1,232)	(615)
Add: Restructuring reserve	239)	283)	288)	477)	140)
Add: Noncontrolling interest	37)	33)	28)	21)	—)
Adjusted total equity (deficit)	6,833)	16,740)	16,459)	14,806)	(7,417)
After Adjustment
Adjusted total capital	67,119)	80,931)	94,034)	101,869)	59,671)

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Current operating lease liabilities (included in Accounts payable and accrued liabilities). See details »

³ Noncurrent operating lease liabilities (included in Other long-term liabilities). See details »

⁴ Net deferred tax assets (liabilities). See details »

Download chart

AbbVie Inc., adjusted net earnings attributable to AbbVie Inc.

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Net earnings attributable to AbbVie Inc.	4,863)	11,836)	11,542)	4,616)	7,882)
Adjustments
Add: Deferred income tax expense (benefit)¹	(2,889)	(1,931)	(898)	(2,325)	122)
Add: Increase (decrease) in restructuring reserve	(44)	(5)	(189)	337)	41)
Add: Other comprehensive income (loss)	(106)	700)	218)	479)	(1,116)
Add: Comprehensive income (loss), net of tax, attributable to noncontrolling interest	10)	9)	7)	6)	—)
After Adjustment
Adjusted net earnings	1,834)	10,609)	10,680)	3,113)	6,929)

¹ Deferred income tax expense (benefit). See details »

Download chart

AbbVie Inc. (NYSE:ABBV)

Adjustments to Financial Statements